Stayble Therapeutics (STABL) Q4 2025 earnings summary

Executive summary

• STA363, a unique injection-based therapy for chronic disc herniation, is positioned for significant value creation for patients and investors, with preparations underway for phase 2b clinical studies.

• Active discussions with strategic investors and partners are ongoing to secure funding for the next development phase, with a financial runway until June 2026.

• Cost-saving measures have been implemented, and the company is focused on advancing both clinical and business development.

Financial highlights

• Operating expenses for 2025 were SEK 6,973k, down from SEK 13,183k in 2024.

• EBIT for 2025 was SEK -6,926k, an improvement from SEK -12,794k in 2024.

• Net result for 2025 was SEK -6,928k, compared to SEK -12,418k in 2024.

• Q4 2025 operating expenses were SEK 1,542k, with EBIT at SEK -1,541k and net result at SEK -1,525k.

• Cash and cash equivalents at year-end 2025 were SEK 2,452k.

Outlook and guidance

• Focus remains on securing financing for the phase 2b study of STA363 and advancing strategic partnerships.

• Confident in establishing optimal conditions for shareholders and the company in the first half of 2026.